Amendment To Cervical Cancer Bill Would Require HPV Labeling For Condoms
This article was originally published in The Gray Sheet
Executive Summary
Condoms manufactured 180 days after the enactment of breast and cervical cancer treatment legislation pending in the House would require a statement in labeling that condoms do not provide adequate protection against the transmission of human papillomavirus (HPV), according to an amendment unanimously adopted by the House Commerce Committee during its Oct. 29 mark-up of the legislation.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: